Drug Search Results
More Filters [+]

SOR-C13

Alternative Names: sor-c13, sorc13, sor c13
Latest Update: 2023-06-23
Latest Update Note: Clinical Trial Update

Product Description

SOR-C13, is a novel, short, synthetic peptide developed from the C-terminal region of Soricidin, our proprietary 54 amino acid peptide. SOR-C13 binds with affinity and selectivity to - and disrupts the function of - TRPV6, a calcium channel over-expressed in solid tumor cancers.Ê (Sourced from: https://www.soricimed.com/sor-c13.htm)

Mechanisms of Action: TRPV6 Inhibitor

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Soricimed Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SOR-C13

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Prostate Cancer|Ovarian Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2018-02835

P1

Completed

Ovarian Cancer|Pancreatic Cancer|Prostate Cancer

2023-06-20

SOR-C13 01

P1

Completed

Ovarian Cancer

2015-07-01

Recent News Events